Ernexa Therapeutics (ERNA) announced the expansion of its Scientific Advisory Board to a combined Scientific and Medical Advisory Board as the company advances toward clinical trials in ovarian cancer and autoimmune disease. This evolution marks a significant milestone in Ernexa’s transition from research to clinical-stage development. This comes on the heels of Ernexa’s recently strengthened financial position and is part of a broader strategy to accelerate its lead programs toward the clinic. Joining the advisory board are two distinguished physicians: Amir Anthony Jazaeri, M.D., a leader in gynecologic oncology at The University of Texas MD Anderson Cancer Center, and Anna Helena Jonsson, M.D., Ph.D., an expert in autoimmune disease and immunology at the University of Colorado School of Medicine. Dr. Jazaeri will help guide the company’s ovarian cancer program into the clinic, while Dr. Jonsson will lead translational strategy for Ernexa’s autoimmune pipeline.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERNA:
- Ernexa secures $6M in second closing under securities purchase agreement
- Eterna Therapeutics Implements 1-for-15 Reverse Stock Split
- Eterna Therapeutics trading halted, news pending
- Ernexa Therapeutics files to sell 57.05M shares of common stock for holders
- Ernexa Therapeutics announces 1-for-15 reverse stock split